Needham Downgrades Apellis Pharmaceuticals (APLS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
Needham analyst Joseph Stringer downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Buy to Hold.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- ONEOK Inc (OKE) PT Raised to $108 at Argus
- El Paso Electric (EE) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
